Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed a share buyback executed on 02 June 2026 under its existing mandate approved on 12 February 2026.

Key transaction details • Shares repurchased: 40,200 H-shares, equivalent to 0.03 % of the company’s issued share capital (excluding treasury shares) prior to the transaction. • Price range: HKD 25.34–28.42 per share, with a volume-weighted average of HKD 26.57. • Aggregate consideration: HKD 1.07 million, settled entirely in cash. • Purpose: All repurchased shares were retained as treasury stock; none were cancelled.

Capital structure impact (post-transaction, 02 June 2026) • Issued shares outstanding (excluding treasury): 135.29 million. • Treasury shares on hand: 0.92 million, equal to 0.68 % of the company’s total issued shares of 136.22 million. • Cumulative repurchases under the current mandate: 924,900 shares, representing 0.679 % of the issued share base as at the mandate date.

Regulatory considerations • The repurchase complied with Hong Kong Main Board Rule 10.06 and related provisions. • A 30-day moratorium on new share issues or the disposal of treasury shares extends through 02 July 2026.

No shares have been earmarked for cancellation, leaving overall share count unchanged at 136.22 million, while market float has been marginally reduced by the transferred shares now held in treasury.